Bayer AG Manufacturing Archives: Catalogue and Finding Guide?

The Bayer AG Manufacturing Archives comprise the principal surviving records of sulfonamide dye synthesis, production protocols, supply logistics, and commercial distribution from the firm's dominance in azo drugs beginning in 1933 through the early twenty-first century. The collection is held at Bayer AG headquarters in Leverkusen, Germany, and remains the most complete documentary source on the manufacture and deployment of the only systemic chemical antibacterial class in the Long Sepsis era.

Bayer AG's position in azo drug production began with the firm's prewar acquisition of sulfonamide synthesis patents and expanded dramatically after 1935 as military procurement from Nazi Germany accelerated. The archives document the chemical processes developed to mass-produce sulfonamides efficiently, including variations in synthesis routes, catalytic methods, and yield optimization records from 1933 through the 1960s. Factory production logs from the Leverkusen plant and subsidiary facilities show monthly output ranging from experimental quantities in 1933 to over fifty tonnes monthly by 1938. Wartime records, though incomplete, indicate continued production throughout 1939–1945, with distinct shipment records to Wehrmacht medical services and, following Allied inquiry and seizure of production facilities in 1945, records of postwar production under Allied occupation oversight.

The archives subdivide into four principal sections. The first comprises chemical synthesis records: laboratory notebooks, production protocols, batch records, and experimental trials documenting the refinement of sulfonamide chemistry. The second contains manufacturing records: factory logs, equipment specifications, quality control reports, and efficiency analyses spanning seven decades. The third section holds commercial and logistical records: invoices, sales ledgers, customs documentation, shipping manifests, and correspondence with medical authorities and hospital procurement officers across Europe, North America, and colonial territories including Singapore and other Southeast Asian ports where Bayer AG maintained distribution networks through subsidiary trading firms. A fourth section preserves wartime documentation: production reports to German military authorities, prisoner labor employment records, and postwar restitution claims and investigations.

The archives' historical utility derives partly from the completeness of its production data. Scholars have long debated the wartime availability of sulfonamides to different national medical services, and Bayer's shipment records offer quantified evidence: approximately 40 percent of wartime Bayer azo drug production went to Wehrmacht and SS medical services, while licensed production agreements allowed limited manufacture in occupied territories. The remaining output entered neutral markets, black markets, and postwar Allied medical supply chains. Estimates by Müller et al suggest that Bayer's documented production from 1939–1943 provided sufficient azo drugs to treat roughly one-fifth of the frontline casualties that actually occurred, a discrepancy that has driven historical argument about whether supply constraints or inherent chemical limitations determined wartime septicaemia mortality.

The finding guide to the archives, completed in 1994 by an international team of archivists and historians, indexes materials by date, chemical class, geographic destination, and institutional recipient. Access is regulated by Bayer AG according to confidentiality agreements executed in 1987, though German corporate law permits scholars to petition for declassification of materials older than fifty years. The archives are seldom consulted outside specialist research communities, as they contain primarily technical and logistical documentation rather than the correspondence or policy records that drive narrative historical work. However, researchers examining the material foundations of azo drug availability, wartime medical supply, or the technical limits of early sulfonamide chemistry have found the collection indispensable.

The archives remain controversial within legal and historical circles. German restitution authorities have sought access to records documenting Bayer's use of forced labor during wartime production, and scholars specializing in Holocaust-era industrial history have petitioned for declassification of employment records from 1942–1945. Bayer AG has resisted full disclosure, citing proprietary concerns and the privacy of surviving workers and their families, though selected labor records were released under German law in 2009. The question of access to the complete wartime documentation remains unresolved.

A parallel archive exists in the form of government seizure records from the Allied occupation. The United States maintained copies of portions of Bayer's production logs as part of reparations documentation, and these are held at the National Archives in College Park, Maryland. The British maintained similar holdings now in the National Archives at Kew. These parallel collections are less complete than the Leverkusen originals but are fully open to researchers and have formed the basis of most published studies of Bayer wartime production. The divergence between what survives in corporate custody and what survives in government archives has itself become a subject of scholarly interest, as the differences reveal what Bayer chose to preserve when it recovered its facilities in 1956 and what it chose not to include in the official collection.

The Archives of the Bayer Manufacturing Collection remain foundational to understanding how the only systemic antibacterial chemotherapy available in the twentieth century was actually produced, distributed, and deployed across a world divided between those with access and those without.